AACE Conference Coverage
AACE Conference Coverage
05/18/2025
Miranda Manier, BA
A study presented at the American Association of Clinical Endocrinology (AACE) Annual Meeting in Orlando, FL examines skin conditions and foot ulcers in patients in Nepal with endocrine disorders and...
05/18/2025
AACE Conference Coverage
AACE Conference Coverage
05/18/2025
Miranda Manier, BA
A study presented at the American Association of Clinical Endocrinology (AACE) Annual Meeting in Orlando, FL examines skin conditions and foot ulcers in patients in Nepal with endocrine disorders and...
05/18/2025
AACE Conference Coverage
AACE Conference Coverage
05/18/2025
Miranda Manier, BA
A study presented at the American Association of Clinical Endocrinology (AACE) Annual Meeting in Orlando, FL examines skin conditions and foot ulcers in patients in Nepal with endocrine disorders and...
05/18/2025
AACE Conference Coverage
AACE Conference Coverage
05/18/2025
Miranda Manier, BA
A study presented at the American Association of Clinical Endocrinology (AACE) Annual Meeting in Orlando, FL examines skin conditions and foot ulcers in patients in Nepal with endocrine disorders and...
05/18/2025
AACE Conference Coverage
AACE Conference Coverage
05/17/2025
Anthony Calabro, MA
A post hoc analysis of the SURMOUNT-1 trial reveals that cardiometabolic improvements achieved after 176 weeks of tirzepatide may diminish significantly within 17 weeks of treatment cessation, particularly...
05/17/2025
AACE Conference Coverage
AACE Conference Coverage
05/17/2025
Anthony Calabro, MA
A post hoc analysis of the SURMOUNT-1 trial reveals that cardiometabolic improvements achieved after 176 weeks of tirzepatide may diminish significantly within 17 weeks of treatment cessation, particularly...
05/17/2025
AACE Conference Coverage
AACE Conference Coverage
05/17/2025
Anthony Calabro, MA
A post hoc analysis of the SURMOUNT-1 trial reveals that cardiometabolic improvements achieved after 176 weeks of tirzepatide may diminish significantly within 17 weeks of treatment cessation, particularly...
05/17/2025
AACE Conference Coverage
AACE Conference Coverage
05/17/2025
Anthony Calabro, MA
A post hoc analysis of the SURMOUNT-1 trial reveals that cardiometabolic improvements achieved after 176 weeks of tirzepatide may diminish significantly within 17 weeks of treatment cessation, particularly...
05/17/2025
AACE Conference Coverage
AACE Conference Coverage
05/17/2025
Anthony Calabro, MA
A post hoc analysis of the SURMOUNT-1 trial reveals that cardiometabolic improvements achieved after 176 weeks of tirzepatide may diminish significantly within 17 weeks of treatment cessation, particularly...
05/17/2025
AACE Conference Coverage
AACE Conference Coverage
05/17/2025
Anthony Calabro, MA
A post hoc analysis of the SURMOUNT-1 trial reveals that cardiometabolic improvements achieved after 176 weeks of tirzepatide may diminish significantly within 17 weeks of treatment cessation, particularly...
05/17/2025